Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma.
Thirty-two toxic oil syndrome (TOS) patients were selected because they presented with scleroderma-like changes and were observed during the first 36 months of evolution of the disease. Initially, these patients presented with a noncardiogenic pulmonary edema, eosinophilia, arthralgia/arthritis, peripheral edema, and myositis. Histologic investigations showed a widespread chronic interstitial infiltrate with lymphocytic vasculitis. They subsequently developed peripheral neuropathy, joint contractures, scleroderma-like changes, Raynaud phenomenon, pulmonary hypertension, sicca syndrome, and liver disease. Biopsy studies during this stage showed fibrosis and obliterating arteriopathy. Late features of TOS are musculoskeletal pain, cramps, livedo reticularis, carpal tunnel syndrome, and digital tuft changes. TOS is a new chemically induced scleroderma-like syndrome with features overlapping those of eosinophilic fasciitis, systemic sclerosis, and forms of localized scleroderma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001937:Brassica; D002648:Child; D002675:Child, Preschool; D004802:Eosinophilia / Q000139:chemically induced; D005208:Fasciitis / Q000139:chemically induced; D005260:Female; D005506:Food Contamination; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007592:Joint Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009468:Neuromuscular Diseases / Q000139:chemically induced; D009821:Oils / Q000506:poisoning*; D011654:Pulmonary Edema / Q000139:chemically induced; D011928:Raynaud Disease / Q000139:chemically induced; D012594:Scleroderma, Localized / Q000139:chemically induced; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D013577:Syndrome
D009821:Oils